Aim: To provide comparative effectiveness evidence for long-acting injectable paliperidone palmitate versus oral atypical antipsychotics. Patients & methods: We performed a retrospective, observational cohort study using patient claims data from Missouri Medicaid to compare the likelihood of emergency department (ED) visits and hospitalizations in the year following drug initiation using multivariable logistic regression. Results: Adjusted odds ratios (AOR) for ED visits (AOR: 0.63; 95% CI: 0.47-0.85) and hospitalizations (AOR: 0.85; 95% CI: 0.64-1.13) were lower in paliperidone palmitate patients, although hospitalizations did not achieve statistical significance. Sensitivity analyses examining mental health-related outcomes and using different analytic strategies for patient selection bias showed directionally similar beneficial effects but were not statistically significant. Conclusion: Early evidence for paliperidone palmitate under real-world conditions is encouraging. However, caution should be taken until additional research substantiates the findings with greater certainty.
Comparative effectiveness evidence is a cornerstone of shared medical decision-making. Following enactment of the Affordable Care Act, comparative effectiveness research (CER) has been embraced by the Patient-Centered Outcomes Research Institute (PCORI) [1] and assessment of treatment options is one of PCORI's national priorities [2] . PCORI's mission is to provide the best available CER evidence to help patients and their healthcare providers make more informed decisions. Ultimately, patients would like to know: "Given my personal characteristics, conditions and preferences, what should I expect will happen to me?"; and clinicians would like to know: "Which treatment strategy should I prescribe for which patients?". Addressing questions of policy importance is also relevant for decision-making at the population system level [3, 4] . For example, healthcare administrators want to know "Given the characteristics of my beneficiaries, what population-level effects should I expect on average in my healthcare system when a new drug is introduced?".
Clinical development programs required for regulatory drug approval demonstrate efficacy and safety (often vs placebo) under controlled conditions. Therefore, when a new drug is introduced into the market there is often a critical gap in comparative effectiveness evidence under common, heterogeneous use conditions. To illustrate how patient-and policy-centered questions could be answered for a newly launched drug, this study used patient claims data to compare the effectiveness of paliperidone palmitate [5] , a longacting second-generation antipsychotic, with the existing alternative treatment strategy of prescribing orally administered secondgeneration antipsychotics in a state Medicaid system.
Patients with serious mental illness experience numerous medication adherence barriers, including cost, access, substance abuse, poor therapeutic alliance with their provider For reprint orders, please contact: reprints@futuremedicine.com and medication beliefs [6] . Long-acting injectable (LAI) antipsychotics are designed to facilitate medication adherence and maintain consistent therapeutic blood concentrations. A systematic literature review of cost-effectiveness studies, which primarily used decision analytic modeling, concluded that atypical LAIs are likely a cost-effective, first-line strategy for managing schizophrenia [7] . Registry studies have shown short- [8, 9] and long-term [10] improvement in clinical outcomes and reductions in hospitalizations and cost of care following initiation with long-acting secondgeneration antipsychotics, including with paliperidone palmitate [11] . However, these studies lacked a comparison group and the independent effects of active treatment versus mode of delivery could not be assessed.
In this observational comparative effectiveness study, the likelihood of hospitalization and emergency department visits were compared in Medicaid patients from the State of Missouri starting paliperidone palmitate versus oral atypical (also known as secondgeneration) antipsychotics. Oral second-generation antipsychotics (as a group) were chosen as the comparator because they represent the alternative treatment decision faced by patients and clinicians, particularly when considering the challenges of drug adherence (i.e., should I take/prescribe the second-generation antipsychotic orally or via a long-acting injection?).
Comparison of therapeutic strategies is also of interest to healthcare administrators making formulary policy decisions. Importantly, this type of comparative approach has been used in previous clinical research studying long-acting antipsychotics [12, 13] .
Patients & methods

Study cohorts (comparison groups)
This retrospective observational study used a new-start cohort design [14] with patient-level data extracted from the Missouri MOHealthNet (Medicaid) and Department of Mental Health administrative databases. Supplementary Figure 1 (see online at http://www. futuremedicine.com/doi/full/10.2217/CER.14.50) shows study population selection. Medicaid clients with a prescription claim for paliperidone palmitate or an oral second-generation antipsychotic between 1 August 2009 and 30 April 2010 were identified. Oral second-generation antipsychotics studied were aripiprazole, asenapine, clozapine, iloperidone, lurasidone, olanzapine, quetiapine, risperidone and ziprasidone. Paliperidone palmitate received US FDA approval in July 2009, which defined the beginning of patient accrual. The most current data available at the time the investigation began (April 2011) were used to define the end of the 12-month follow-up period. Medicaid clients who were Medicare eligible or had Medicaid eligibility less than 12 months before and after the first qualifying pharmacy (Index) claim date were excluded because claims data or observation follow-up would be incomplete. The primary analysis compared outcomes in the new start cohorts of paliperidone palmitate (n = 296) and oral second-generation antipsychotic (n = 8675) users. The study received approval from the Colorado Multiple Institutional Review Board and adhered to Data Use Agreements with the State of Missouri.
Healthcare outcomes
Hospitalization and emergency department (ED) visits were the primary outcomes studied. Occurrence, frequency of occurrence, and cumulative length of stay (for hospitalizations) were summarized for the baseline period (defined as the year preceding the Index claim date) and the follow-up period (defined as the year after drug initiation). All-cause and mental health outcomes were modeled separately. An outcome was defined as mental health if the first diagnosis of the claim record was for a mental disorder contained in the Agency for Healthcare Research and Quality (AHRQ) Mental Health and Substance Abuse Classification [15] (Supplementary Material).
Baseline patient-mix characteristics
Patient age (in years), sex and race were identified. Patient environment (where they lived and received care) was also examined. Urbancity (as defined by the AHRQ Area Resource File) was determined using county of residence. Patients were categorized into state-defined mental health service areas using county and zip codes. Patients receiving care in Community Mental Health Centers (CMHC) were identified.
Mental health conditions were identified using International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes ascertained from medical claims in the year before the Index date and classified into 13 categories using AHRQ's classification scheme (Supplementary Material) [16] . Each patient was categorized based on the number of diagnostic categories recorded: 0 (none), 1-2, or 3 or more. A diagnosis of schizophrenia was of special interest, given paliperidone palmitate's approved indication; it was defined as at least one medical claim with diagnosis code ICD-9-CM 295 (excluding 295.7, schizoaffective disorder).
Compliance with the cohort drug was defined as the percent days covered during the year after the Index date [17] . Additional psychotropic drug use (another marker for disease severity) was defined as a pharmacy claim for an antidepressant, mood stabilizer, benzodiaz-future science group Baseline cardiometabolic comorbidities (diabetes, lipid disorders, hypertension and diseases of the heart) were identified using ICD-9-CM diagnosis codes and AHRQ's classification scheme (Supplementary Material) . Cardiometabolic disorders are a significant source of morbidity [18] and mortality [19, 20] in patients with mental illness, and were included as a measure of other major nonpsychiatric causes of ED visits, hospitalizations and outpatient office visits (defined by CPT codes, Supplementary Material).
Statistical analyses
The primary analysis compared outcomes in the new start cohorts. First, ArcGIS10.0 (ESRI, CA, USA) was used to map the population prevalence of oral second-generation antipsychotic and paliperidone palmitate prescription claims per 100,000 population by mental health service area. Descriptive statistics were performed on baseline patient characteristics. Categorical characteristics were summarized by frequency and compared using Pearson's chi-square test of association. The mean (standard deviation) was used to describe continuous characteristics (or median [interquartile ranges] for skewed distributions); means were compared between cohorts using a t-test (or Kruskal-Wallis test for medians).
ED visits and hospitalizations were the primary outcomes compared using an as-treated approach. In other words, the effectiveness results are based on the initial treatment strategy selected (as evidenced by the index prescription claim) and not on the sum of the treatments eventually received (e.g., all healthcare utilization), as would be done in a per-protocol efficacy analysis. Multivariate logistic regression was used to separately model the likelihood of an ED visit (allcause and mental health related) and hospital admission (all-cause and mental health related) occurring in the year after drug initiation to determine whether occurrences varied between new users of paliperidone palmitate and oral second-generation antipsychotics. Models were adjusted for the following prespecified variables: cohort (paliperidone palmitate or oral second-generation antipsychotic), patient demographics (age, sex, race), urbanicity, schizophrenia, baseline mental health and cardiometabolic comorbidites, baseline psychotropic drug use, healthcare utilization (case management, outpatient visits), and antipsychotic medication adherence. The all-cause models were adjusted for frequency of hospitalizations and ED visits in the baseline period; and the mental health models were adjusted for the frequency of mental health hospitalizations and mental health ED visits in the baseline period. As a secondary analysis for hospitalization outcomes, differences in cumulative length of stay (cLOS) were modeled using a two-part model. Part one modeled the probability of having cLOS >0 using logistic regression. Part two assessed cumulative length of stay when cLOS >0 using linear regression with log transformation of cLOS. Adjustments factors were similar to those from the primary models.
All statistical analyses used SAS version 9.3 (SAS Institute, NC, USA). Adjustment for multiple comparisons was not performed for the analysis [21] .
Sensitivity analyses
The primary analysis (using a traditional approach of covariate-adjusted modeling) was prespecified in the study protocol; however, during the course of the study, AHRQ published guidelines for observational CER studies recommending other techniques to overcome self-selection inherent to observational studies. Rather than change the primary analysis post-hoc, we added additional sensitivity analyses following AHRQ's bestpractice recommendations to test the robustness of the primary analysis [22] .
The sensitivity analyses performed used three separately defined subcohorts: propensity score matching; provider restricted; and patient restricted. Propensity score matching is used for reducing the effects of confounding due to nonrandomized treatment allocation in observational studies [23] . Propensity-matched cohorts (n = 214 pairs) were created using one-to-one propensity matching with a greedy algorithm [24] . Propensity was scored on patient demographics (age, sex, race, urbanicity), schizophrenia, baseline mental health and cardiometabolic comorbidities, psychotropic drug use, and healthcare utilization (care at a CMHC, case management, outpatient visits, emergency department visit and hospitalization). The provider-restricted cohorts (n = 296 paliperidone palmitate; n = 4778 oral second-generation antipsychotics) were created by including only patients from the new start cohort treated by providers who prescribed both paliperidone palmitate and oral second-generation antipsychotic medications because variation in treatment selection might arise from differences in sales visits and/or inservice education during the observation period following the drug's launch [25] . The patient-restricted cohorts (n = 201 paliperidone palmitate; n = 595 oral second-generation antipsychotics) were included only adult patients (age: 18-64 years) with a diagnosis of schizophrenia to restrict the analysis to patients for whom paliperidone palmitate is indicated per product 
Results
As anticipated for a newly approved drug, paliperidone palmitate was prescribed significantly less often than oral second-generation antipsychotics during the study period. The population prevalence of new starts is mapped by Mental Health Service Area in Figure 1 . Paliperidone palmitate use was more prevalent in the central and southeast corner of the state, whereas oral second-generation antipsychotic use was more prevalent in the southern half of the state. Table 1 compares baseline patient characteristics. Patients starting paliperidone palmitate were more likely to be older, male, black, receiving care at a CMHC and under case management than patients starting oral second-generation antipsychotics. Patients starting paliperidone palmitate had more mental health and substance-abuse disorders than patients starting oral second-generation antipsychotics. The subset of patients with a diagnosis of schizophrenia was 63.5% in the paliperidone palmitate group compared with 4.9% in the oral second-generation antipsychotics group (p < 0.001). Conversely, 19.3% of patients with schizophrenia and 13.8% of patients who received case management were started on paliperidone palmitate (compared with the mean of 3% of patients who started paliperidone palmitate overall). On average, patients in the paliperidone palmitate group had filled prescriptions for two different antipsychotics in the year before starting paliperidone palmitate; approximately 15% of patients had filled prescriptions for ≥4 antipsychotics. In comparison, 3.6% of patients in the oral secondgeneration antipsychotic group had an antipsychotic prescription in the past year.
Patients in the paliperidone palmitate group were more likely to have diagnoses for diabetes (21.6 vs 10.7%; p < 0.001); dyslipidemia (26.4 vs 12.1%; p < 0.001), hypertension (37.5 vs 19.1%; p < 0.001) and other diseases of the heart (31.1 vs 23.9%; p < 0.01) compared with patients in the oral second-generation antipsychotics group. This finding may be modulated by a greater propensity for paliperidone palmitate use among African-Americans who have higher rates of diabetes and hypertension. Patients starting paliperidone palmitate were less likely to have had a mental health outpatient visit (23.0 vs 29.4%; p = 0.02) or other outpatient visit (70.3 vs 82.3%; p < 0.001) in the past year compared with patients starting oral second-generation antipsychotics.
Supplementary Table 1 presents patient characteristics in the propensity score matching, providerrestricted and patient-restricted cohorts. Following propensity score matching, patient characteristics were balanced between cohorts with the exception of schizophrenia and other psychotic disorders (although the prevalence was more balanced than in the new start cohort). The patient-restricted cohorts appeared similar in age and baseline mental health characteristics, but there were still differences in baseline psychotropic drug use and healthcare utilization. Patient profiles in the provider-restricted cohorts appeared similar to the new start cohorts.
Outcomes of interest
In the year following drug initiation, patients in the paliperidone palmitate group had more pharmacy claims than patients in the oral second-generation antipsychotics group (median 9 claims [IQR: 4-13] vs median 6 [IQR: 2-11], respectively; p < 0.001). This corresponded to a higher median percent of days covered in the paliperidone palmitate cohort com-future science group 
The adjusted likelihoods of all-cause and mental health ED visits or hospitalizations after drug initiation are shown in Figure 2 for the primary analysis and the sensitivity analyses cohorts (see Supplementary Tables 3-6 for full multivariable results). The adjusted likelihood of an event in the new start cohorts (primary analysis) was reduced in the paliperidone palmitate group compared with the oral second-generation antipsychotic group by 37% for allcause ED visits (AOR: 0.63), 23% for mental health ED visits (AOR: 0.77), 15% for all-cause hospitalization (AOR: 0.85), and 19% for mental health hospitalization (AOR: 0.81). Statistical significance at an alpha level of 0.05 was achieved for the likelihood of an allcause ED visit. In general, the sensitivity analyses performed in the propensity-matched, provider-restricted and patient-restricted cohorts showed qualitatively similar point estimates after adjustment. Statistical significance was achieved in the provider-restricted cohorts for the likelihood of an all-cause and mental health ED visit.
Prior to adjustment, the cumulative length of stay during the 12 months after drug initiation, was statistically longer for the paliperidone palmitate group compared with oral second-generation antipsychotics group who were hospitalized (median [range], days: 10 (1-200) vs 7 [1-546]; p < 0.001). After adjustment, the cumulative length of stay among those hospitalized did not differ between cohorts.
Discussion
This early, postmarketing comparative effectiveness study of paliperidone palmitate in the Missouri Medicaid healthcare system found a statistically significant reduction in the adjusted likelihood of an all-cause ED visit compared with patients starting an oral secondgeneration antipsychotic. The adjusted likelihood of hospitalization was also directionally lower in paliperidone palmitate patients, but did not achieve statistical significance.
The prespecified primary analysis used traditional covariate adjustment methods. After the study began, AHRQ published guidelines for observational CER studies recommending other techniques to address selection biases inherent to observational studies [22] . Therefore, sensitivity analyses were added to examine mental health-related outcomes and different recommended cohort specifications and adjustment strategies. Results from these analyses generally showed directionally similar effect sizes, although most were statistically nonsignificant. The propensity-adjusted sensitivity analyses are of particular relevance as this method is considered a primary analytic CER strategy. In those results, the adjusted likelihood of an ED visit and hospitalization were attenuated from the primary effects; however, the confidence intervals were wider. Although the results in total are directionally encouraging, caution should be taken until additional research substantiates the findings with greater certainty.
To our knowledge, this was the earliest comparative effectiveness evaluation of paliperidone palmitate under real-world use conditions using CER methodology standards specified by AHRQ [22] . Mental healthcare treatment choices and policies are often uninformed by adequate numbers and types of studies, especially involving patients with multiple comorbidities in typical care settings [26] . Registry studies of patients with schizophrenia receiving other long-acting antipsychotics have shown pre-post reductions in psychiatric hospitalizations in the range of 20-50% [8] [9] [10] . However, those studies lacked a comparison group and so relative advantage versus oral therapies was unknown. Previous studies have also been largely limited to patients with a schizophrenia diagnosis. The present study provides both schizophrenia-specific findings and population-level findings for all patients receiving medication regardless of indication. Current Federal law and regulation does not allow Medicaid, the largest funder of long-acting depot antipsychotic medications, to absolutely restrict usage to specific diagnosis, so diagnostic-specific studies are less helpful in making formulary access decisions. Results from the study were shared with state Medicaid and mental healthcare policy-makers in real time to inform decision-making.
Hospitalizations and ED visits were studied because they could be easily and objectively ascertained from the available administrative health records, and were relevant outcomes for patients, clinicians and mental healthcare policy-makers. The suggestion of a larger effect in reducing the likelihood of an ED visit with long-acting medication, compared with the effect size for the likelihood of future science group
Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics Research Article Research Article Morrato, Parks, Campagna, Muser, Thomas, Fang & Doshi hospitalization, warrants further study. At a population level, monthly visits for paliperidone palmitate injections might provide the benefit of more frequent provider contact, reducing the need for emergency services, especially among those not under close care management.
Study limitations should be acknowledged. First, this is an observational study where antipsychotic treatment is not randomized. The unadjusted results show that patients receiving paliperidone palmitate in the first year after market introduction were sicker; therefore, careful consideration concerning selection bias when evaluating treatment effectiveness is necessary. The comparative effectiveness in both unadjusted results and adjusted results may have been influenced by baseline differences in who was selected to receive which type of antipsychotic.
Leaders in the field have argued that observational studies can address issues that are difficult to study more rapidly (e.g., early postmarketing experience) and that "many clinical and policy decisions do not require the very high levels of certainty provided by large, rigorous randomized trials" [27] . They have concluded that "highquality observational studies can effectively complement findings from randomized trials, and that communicating their results to patients and clinicians is warranted" [28] . Interestingly, Kane et al. argue that conventional randomized controlled trials may not be the best CER study design to compare long-acting injectables with oral second-generation antipsychotics because RCTs reflect drug adherence under trial conditions, not real-world practice; thereby, a conventional RCT might underestimate treatment differences in clinical practice [13] .
The internal validity of the study was strengthened by its new-start cohort design, prespecified objective end points, and consistency of findings across multiple sensitivity analyses using different cohort definitions and adjustment strategies [22] . External validity is strengthened by the fact that Missouri Medicaid has a similar demographic and healthcare utilization profile as national Medicaid populations [29] . However, this study reports average population-level effects, so further research is needed to examine individual treatment effects.
A second limitation is the small sample of patients starting paliperidone palmitate, due in part to its targeted usage compared with oral second-generation antipsychotics and the fact that the evaluation studies a new market entrant. As a result, the ability to demonstrate statistical significance or more in-depth examination of important subgroups, such as those with schizophrenia, may have been hindered. Nonetheless, there is value in early market learning to help address patient-and policy-centered questions. AcademyHealth reported that timely research is essential to informing healthcare policy; in fact, policy-makers advised researchers to give their best estimates even if the current evidence is 'best available' versus ' unassailably the best' [30] .
future science group
Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics Research Article Last, long-term health outcomes and costs are important for mental healthcare policy and practice, but have been understudied in CER [26] . Examination of 12-month outcomes is a strength of the present study. However, future research should continue to examine the cost-effectiveness of paliperidone palmitate. Comparisons with generic long-acting, first-generation antipsychotics is of interest to decision makers and clinicians [31] .
Conclusion
In summary, this early postmarketing comparative effectiveness evaluation of long-acting paliperidone palmitate versus oral second-generation antipsychotics under real-world use conditions found a significant reduction in the likelihood of an ED visit and a smaller directional benefit (albeit not statistically significant) in the likelihood of hospitalization. The findings were directionally similar across multiple sensitivity analyses using different cohort definitions and recommended adjustment strategies for causal inference, although the results did not achieve statistical significance. This should be reassuring to patients, clinicians and health system administrators considering the use of a long-acting antipsychotic. Further research is necessary to confirm the findings using a larger sample of patients and in other clinical settings; and to continue to investigate the impact of patient selection bias on outcomes as the propensity for treatment with paliperidone palmitate evolves over time.
Future perspective
Rapid-cycle research has been adopted by the federal Center for Medicare and Medicaid (CMS) Innovation [30] . CMS envisions a future in which ineffective ideas 'fail fast' and successful innovations spread quickly. Accountable Care Organizations are also moving toward real-time analytics and performance indicators. In the future, high-quality observational CER of new market entrants can contribute to a rapid-learning healthcare system. This CER study aimed to detect early signals of effectiveness for a newly launched drug in much the same way as public health officials might monitor for early drug safety signals via active post marketing surveillance. From a pharmacovigilance perspective, the consistent magnitude of beneficial effects in the primary and sensitivity analyses is encouraging. The results indicate that the comparative effectiveness of paliperidone palmitate should continue to be monitored in larger populations to increase precision and confirm the trends reported in this early analysis. However, to truly inform real-time decision-making, the CER field would need to evolve such that observational research is conducted prospectively in parallel with product launches rather than the current state in which retrospective studies (like ours) are not initiated until after a product is already on the market.
One might also envision a future with CER monitoring boards of independent experts who monitor effectiveness outcomes while market expansion is ongoing; this would be analogous to a drug safety monitoring board (DSMB) monitoring patient safety and treatment efficacy data while a clinical trial is ongoing. Statistical methods for active postmarketing CER surveillance might be developed as they have been for DSMB decision-making. For example, an analogous 'futility index', used by DSMBs and defined as the conditional probability that the trial will fail to demonstrate a benefit of therapy given the observed results, could be developed for CER outcomes. In this context, the trial represents the natural experiment of a new product introduction. The recent intense public debate about the value versus price of extremely expensive drugs, such as Solvaldi (sofosbuvir) for the treatment of Hepatitis C, demonstrates the need for such an analytic approach to monitor the comparative effectiveness of new agents while market expansion is occurring. However, as in DSMB decision-making, the need for caution and patience must be highlighted, lest a decision to disfavor a product be taken too quickly [32] . Complex therapy, especially those involving patients with multiple comorbidities, may be associated with a learning curve, and imperfect observational data and selection biases may confound the findings. The challenge will be to develop statistical approaches and reporting norms to meet the need for high-quality rapid-cycle CER research of new products. No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved. •• Evaluated the efficacy and safety of paliperidone palmitate when used for the treatment of schizophrenia and schizophrenia-like illnesses. In short-term studies, paliperidone palmitate was found to be a more effective antipsychotic than placebo. The adverse effects of paliperidone palmitate are similar to those of oral paliperidone, oral risperidone and risperidone longacting injection. In two short-term studies, flexibly-dosed paliperidone palmitate is roughly equivalent in efficacy and tolerability to flexibly-dosed risperidone long-acting injection. •• This pre-post registry study followed 200 consecutively treated patients with serious mental illness receiving paliperidone palmitate therapy for 1 year. The number of hospitalizations and length of stay were lower on paliperidone palmitate therapy than in the year before drug initiation. A limitation of this design is that there was no comparator group, which the present study sought to address.
Executive summary
• Healthcare policy-makers and clinicians desire comparative effectiveness evidence in real-world settings for newly introduced drugs. Unfortunately, this evidence is often unavailable or lacking rigor.
• This study is a case example of generating early comparative effectiveness research (CER) evidence using patient claims data from a real-world Medicaid setting in the year following product launch for a long-acting injectable antipsychotic (paliperidone palmitate).
• Poor drug adherence with second-generation oral antipsychotics has been correlated with worse clinical trajectory and increased hospitalization for persons with serious mental illness. Long-acting antipsychotics may improve adherence and result in reduced emergency department visits and hospitalizations.
• This study of early postmarketing experience yielded findings that showed that paliperidone palmitate treatment resulted in a statistically significant 37% reduction in the adjusted likelihood of an all-cause emergency department visit and a 15% reduction in hospitalization that did not achieve statistical significance in the year following drug initiation compared with patients starting an oral second-generation antipsychotic. Consistent magnitude of beneficial effects in the sensitivity analyses is encouraging.
• This study illustrates two challenges encountered when generating rapid-cycle learning on a new product with observational CER -namely, the need to address patient selection biases (often stronger at the time of market entry) and limited precision of the estimates of effect for newly launch products with select use. These limitations need to be balanced with the value of early real-time market learning for policy-makers and clinicians. Further postmarketing CER research is needed to confirm these findings and to investigate the impact of patient selection bias on outcomes as the propensity for treatment with paliperidone palmitate evolves over time.
• • This report summarizes key informant interviews with government agency analysts, nongovernmental experts and other healthcare policy-makers regarding knowledge gaps and research needs related to Medicare. It discusses the role of CER and the need for rapid-cycle research for timely policy making.
